Biomarker & Intervention Discovery

Metabolic Syndrome

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ACE 229AGTR1 249IL6 173INSR 256IRS1 16LEPR 6LPL 60PPARG 231PRKAA1 202TNF 277
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SALVIANOLIC ACID B ? unclear Mechanistic
CANDOXATRIL ? unclear Mechanistic
CILAZAPRIL inhibits Mechanistic
TP0556351 inhibits Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
SILDENAFIL ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
RESCINNAMINE ? unclear Mechanistic
SPIRAPRIL ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
ARGIPRESSIN ? unclear Mechanistic
METOPROLOL ? unclear Mechanistic
DELAPRIL inhibits Mechanistic
ACETYLCHOLINE ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
IMIDAPRIL inhibits Mechanistic
MALATHION inhibits Mechanistic
MOEXIPRIL ? unclear Mechanistic 56.0 nM (IC50)
VORINOSTAT ? unclear Mechanistic
ILEPATRIL inhibits Mechanistic
RXP470.1 inhibits Mechanistic
CGS-27023A ? unclear Mechanistic
NITROPRUSSIDE ? unclear Mechanistic
ENALAPRILAT ANHYDROUS inhibits Mechanistic 1.2 nM (IC50)
TORSEMIDE ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
FOSINOPRIL ? unclear Mechanistic
FUROSEMIDE ? unclear Mechanistic
TEMOCAPRIL HYDROCHLORIDE ? unclear Mechanistic
BENAZEPRIL HYDROCHLORIDE inhibits Mechanistic
CARBARIL inhibits Mechanistic
BUPROPION HYDROCHLORIDE ? unclear Mechanistic
QUINAPRIL ? unclear Mechanistic 8.3 nM (IC50)
COMPOUND 1 [PMID: 24900526] inhibits Mechanistic
COMPOUND 20 [PMID: 22153340] inhibits Mechanistic
BUMETANIDE ? unclear Mechanistic
GALLOPAMIL ? unclear Mechanistic
FLUOXETINE HYDROCHLORIDE ? unclear Mechanistic
AZD6605 inhibits Mechanistic

Showing top 40 of 229 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CANDESARTAN CILEXETIL inhibits Mechanistic
CHEMBL:CHEMBL586135 ? unclear Mechanistic
VALSARTAN inhibits Mechanistic 4700.0 nM (Ki)
EPROSARTAN MESYLATE inhibits Mechanistic
FIMASARTAN inhibits Mechanistic
ASCORBIC ACID ? unclear Mechanistic
OLMESARTAN MEDOXOMIL inhibits Mechanistic
AZILSARTAN MEDOXOMIL inhibits Mechanistic
THERAPEUTIC ANDROSTANOLONE ? unclear Mechanistic
CHEMBL:CHEMBL347610 ? unclear Mechanistic
CHEMBL:CHEMBL421088 ? unclear Mechanistic
LOSARTAN POTASSIUM inhibits Mechanistic 5.5 nM (IC50)
CHEMBL:CHEMBL1492017 ? unclear Mechanistic
SPARSENTAN inhibits Mechanistic
SODIUM CHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL261693 ? unclear Mechanistic
CHEMBL:CHEMBL1972216 ? unclear Mechanistic
EPROSARTAN ? unclear Mechanistic 7.3 nM (IC50)
C-FOS ANTISENSE ? unclear Mechanistic
SARALASIN ACETATE inhibits Mechanistic
IRBESARTAN inhibits Mechanistic 1.1 nM (Ki)
DISULFIRAM ? unclear Mechanistic
SAPRISARTAN ? unclear Mechanistic
H2O2 ? unclear Mechanistic
CHEMBL:CHEMBL591834 ? unclear Mechanistic
CAPTOPRIL ? unclear Mechanistic
ANGIOTENSIN II ? unclear Mechanistic
CHEMBL:CHEMBL400912 ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
IDOXIFENE ? unclear Mechanistic
CHEMBL:CHEMBL528694 ? unclear Mechanistic
IL-6 ? unclear Mechanistic
ANGIOTENSIN II ACETATE activates Mechanistic
LEVODOPA ? unclear Mechanistic
GAMMA-INTERFERON ? unclear Mechanistic
AZILSARTAN KAMEDOXOMIL inhibits Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
CHEMBL:CHEMBL1445650 ? unclear Mechanistic
MUSCLE RELAXANT ? unclear Mechanistic
CL-329167 ? unclear Mechanistic

Showing top 40 of 249 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic
ZILTIVEKIMAB ~ modulates Mechanistic
CHINESE HERBS ? unclear Mechanistic
PF-04236921 inhibits Mechanistic
MRA 003 US inhibits Mechanistic
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic
BINETRAKIN ? unclear Mechanistic
IBUDILAST ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
SILTUXIMAB inhibits Mechanistic
METRONIDAZOLE ? unclear Mechanistic
CLAZAKIZUMAB inhibits Mechanistic
GALLIUM NITRATE ? unclear Mechanistic
INTERFERON ALFA-2B ? unclear Mechanistic
DULOXETINE HYDROCHLORIDE ? unclear Mechanistic
MEDI-5117 inhibits Mechanistic
GEMFIBROZIL ? unclear Mechanistic
BIAFINE CREAM ? unclear Mechanistic
ETANERCEPT ? unclear Mechanistic
ELSILIMOMAB inhibits Mechanistic
SAQUINAVIR ? unclear Mechanistic
INFLIXIMAB ? unclear Mechanistic
LINEZOLID ? unclear Mechanistic
IFOSFAMIDE ? unclear Mechanistic
OLOKIZUMAB inhibits Mechanistic
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
SELENIUM ? unclear Mechanistic
SIRUKUMAB inhibits Mechanistic
PEGINTERFERON ALFA-2B ? unclear Mechanistic
ECHINACEA PREPARATION ? unclear Mechanistic
ENZYME INHIBITOR ? unclear Mechanistic
FENOFIBRATE MICRONIZED ? unclear Mechanistic
VITAMIN K ? unclear Mechanistic
PEGINTERFERON ALFA-2A ? unclear Mechanistic
RIBAVIRIN ? unclear Mechanistic
VITAMIN A PALMITATE ? unclear Mechanistic
ARSENIC TRIOXIDE ? unclear Mechanistic
DIHYDROSPHINGOSINE ? unclear Mechanistic
LEVOFLOXACIN ANHYDROUS ? unclear Mechanistic

Showing top 40 of 173 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
TESOFENSINE ? unclear Mechanistic
INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN activates Mechanistic
GO-6976 ? unclear Mechanistic
INSULIN ZINC, PROMPT activates Mechanistic
INSULIN PURIFIED PORK activates Mechanistic
INSULIN ZINC SUSP EXTENDED PURIFIED BEEF activates Mechanistic
INSULIN ZINC, EXTENDED activates Mechanistic
INSULIN ZINC SUSP EXTENDED BEEF activates Mechanistic
INSULIN ZINC SUSP BEEF activates Mechanistic
INSULIN SENSITIZER S-707106 ? unclear Mechanistic
SP-600125 ? unclear Mechanistic
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic
INSULIN DETEMIR activates Mechanistic
INSULIN DEGLUDEC activates Mechanistic
AEW-541 ? unclear Mechanistic 2300.0 nM (IC50)
ILORASERTIB ? unclear Mechanistic
NVP-TAE684 ? unclear Mechanistic
INSULIN ASPART PROTAMINE RECOMBINANT activates Mechanistic
INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF activates Mechanistic
INSULIN, PROTAMINE ZINC activates Mechanistic
INSULIN TREGOPIL activates Mechanistic
INSULIN, REGULAR, HUMAN activates Mechanistic
PF-562271 ? unclear Mechanistic
INSULIN SUSP PROTAMINE ZINC PURIFIED PORK activates Mechanistic
RECOMBINANT HUMAN KALLIKREIN-1 ? unclear Mechanistic
LINIFANIB ? unclear Mechanistic
INSULIN [INJECTION], BIPHASIC activates Mechanistic
INSULIN HUMAN, ISOPHANE activates Mechanistic
INSULIN SUSP ISOPHANE PURIFIED PORK activates Mechanistic
INSULIN ZINC SUSP PURIFIED PORK activates Mechanistic
RG-1530 ? unclear Mechanistic
EPIRUBICIN ? unclear Mechanistic
INSULIN ASPART PROTAMINE, HUMAN activates Mechanistic
TOZASERTIB ? unclear Mechanistic 506.0 nM (Kd)
TOPIRAMATE ? unclear Mechanistic
LINSITINIB inhibits Mechanistic
INSULIN LISPRO activates Mechanistic
INSULIN LISPRO PROTAMINE RECOMBINANT activates Mechanistic
INSULIN SUSP ISOPHANE BEEF/PORK activates Mechanistic
MITOGLITAZONE ? unclear Mechanistic

Showing top 40 of 256 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
AGANIRSEN ? unclear Mechanistic
CYCLOPHOSPHAMIDE ANHYDROUS ? unclear Mechanistic
FLUOROURACIL ? unclear Mechanistic
DEHYDRATED ALCOHOL ? unclear Mechanistic
PRASTERONE ? unclear Mechanistic
EPIRUBICIN ? unclear Mechanistic
INOSITOL ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
CHEMBL1685056 inhibits Mechanistic 50.0 nM (Kd)
CHEMBL1685055 inhibits Mechanistic 150.0 nM (Kd)
CHEMBL1681823 inhibits Mechanistic 50.0 nM (Kd)
CHEMBL4536878 inhibits Mechanistic 120.0 nM (Kd)
CHEMBL4591779 inhibits Mechanistic 16200.0 nM (Kd)
CHEMBL4530453 inhibits Mechanistic 1600.0 nM (Kd)
CHEMBL1572640 inhibits Mechanistic 3300.0 nM (Kd)
CHEMBL4576057 inhibits Mechanistic 16400.0 nM (Kd)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MIBAVADEMAB activates Mechanistic
SIMVASTATIN ? unclear Mechanistic
VALPROIC ACID ? unclear Mechanistic
METRELEPTIN activates Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
SETMELANOTIDE ? unclear Mechanistic
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INOSITOL ? unclear Mechanistic
DEXTRAN SULFATE ? unclear Mechanistic
ASPARAGINASE ? unclear Mechanistic
RETINYL ACETATE ? unclear Mechanistic
RECOMBINANT INTERLEUKIN ? unclear Mechanistic
ANABOLIC STEROID ? unclear Mechanistic
OXIDOPAMINE ? unclear Mechanistic
ISOTRETINOIN ? unclear Mechanistic
FOLIC ACID ? unclear Mechanistic
LYMPHOKINE-ACTIVATED KILLER CELLS ? unclear Mechanistic
MIFEPRISTONE ? unclear Mechanistic
ACARBOSE ? unclear Mechanistic
H2O2 ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
RECOMBINANT LYMPHOKINE ? unclear Mechanistic
CLOFIBRATE ? unclear Mechanistic
TRIAMCINOLONE ? unclear Mechanistic
ADRIAMYCIN ? unclear Mechanistic
LABETALOL ? unclear Mechanistic
LOVASTATIN ? unclear Mechanistic
INSULIN, REGULAR, HUMAN ? unclear Mechanistic
DIAZOXIDE ? unclear Mechanistic
PIOGLITAZONE HYDROCHLORIDE ? unclear Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
RESERPINE ? unclear Mechanistic
ORLISTAT ? unclear Mechanistic 66.0 nM (IC50)
NADOLOL ? unclear Mechanistic
IBROLIPIM ? unclear Mechanistic
CHEMBL339297 inhibits Mechanistic 200.0 nM (IC50)
TOLYL BORONIC ACID inhibits Mechanistic 9000.0 nM (IC50)
CHEMBL1952294 inhibits Mechanistic 9000.0 nM (IC50)
CHEMBL1952295 inhibits Mechanistic 8000.0 nM (IC50)
CHEMBL1952296 inhibits Mechanistic 15000.0 nM (IC50)
CHEMBL1952297 inhibits Mechanistic 30000.0 nM (IC50)
CHEMBL485946 inhibits Mechanistic 42000.0 nM (IC50)
CHEMBL1952298 inhibits Mechanistic 50000.0 nM (IC50)
CHEMBL1952299 inhibits Mechanistic 50000.0 nM (IC50)
CHEMBL1952302 inhibits Mechanistic 25000.0 nM (IC50)
CHEMBL1952303 inhibits Mechanistic 50000.0 nM (IC50)
CHEMBL1952304 inhibits Mechanistic 55000.0 nM (IC50)

Showing top 40 of 60 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
METHOXYCHLOR ? unclear Mechanistic
CHEMBL:CHEMBL2208197 ? unclear Mechanistic
PROPYLPYRAZOLETRIOL ? unclear Mechanistic
LANIFIBRANOR activates Mechanistic
PROPYLPARABEN ? unclear Mechanistic
ABIETIC ACID ? unclear Mechanistic
KEPONE ? unclear Mechanistic
SPIRONOLACTONE ? unclear Mechanistic
FLUOXASTROBIN ? unclear Mechanistic
ROSIGLITAZONE MALEATE activates Mechanistic
CHEMBL:CHEMBL2178583 ? unclear Mechanistic
NAVEGLITAZAR activates Mechanistic
CELECOXIB ? unclear Mechanistic
SHINPTEROCARPIN ? unclear Mechanistic
PSAMMAPLIN A ? unclear Mechanistic
TECNAZENE ? unclear Mechanistic
MYCOPHENOLATE ? unclear Mechanistic
CHEMBL:CHEMBL1833984 ? unclear Mechanistic
IMIGLITAZAR activates Mechanistic
ROSIGLITAZONE ? unclear Mechanistic 250.0 nM (IC50)
CLX-0921 activates Mechanistic
AVE0847 activates Mechanistic
CHLORFENAPYR ? unclear Mechanistic
PIOGLITAZONE HYDROCHLORIDE activates Mechanistic
PROCHLORAZ ? unclear Mechanistic
MESALAMINE activates Mechanistic
BEZAFIBRATE activates Mechanistic
CHEMBL:CHEMBL312032 ? unclear Mechanistic
ISOSILYBIN A ? unclear Mechanistic
AMORFRUTIN A ? unclear Mechanistic
NALED ? unclear Mechanistic
TROGLITAZONE activates Mechanistic 302.0 nM (Ki)
PROSTAGLANDIN D2 ? unclear Mechanistic
INT131 ~ modulates Mechanistic
EFATUTAZONE HYDROCHLORIDE activates Mechanistic
FLUORODIFEN ? unclear Mechanistic
FLUDIOXONIL ? unclear Mechanistic
ESTRADIOL VALERATE ? unclear Mechanistic
CHEMBL:CHEMBL166112 ? unclear Mechanistic
BENSULIDE ? unclear Mechanistic

Showing top 40 of 231 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
GW441756X ? unclear Mechanistic
PD-0166285 ? unclear Mechanistic 316.23 nM (Ki)
CENISERTIB ? unclear Mechanistic
CYC-116 ? unclear Mechanistic 501.19 nM (Ki)
PENTOSTATIN ? unclear Mechanistic
PALBOCICLIB ? unclear Mechanistic
JNJ-7706621 ? unclear Mechanistic 1700.0 nM (Kd)
PF-562271 ? unclear Mechanistic
TOZASERTIB ? unclear Mechanistic 1100.0 nM (Kd)
STREPTOZOCIN ? unclear Mechanistic
DOVITINIB ? unclear Mechanistic 520.0 nM (Kd)
TYROSINE KINASE INHIBITOR ? unclear Mechanistic
METFORMIN ? unclear Mechanistic
RG-1530 ? unclear Mechanistic
LY-2090314 ? unclear Mechanistic 630.96 nM (Ki)
ADENOSINE DEAMINASE INHIBITOR ? unclear Mechanistic
SAPONARIN ? unclear Mechanistic
CHEMBL:CHEMBL587615 ? unclear Mechanistic
CHEMBL:CHEMBL1997335 ? unclear Mechanistic
ENTRECTINIB ? unclear Mechanistic 251.19 nM (Ki)
SIROLIMUS ? unclear Mechanistic
ILORASERTIB ? unclear Mechanistic
TETRADECANOYLPHORBOL ACETATE ? unclear Mechanistic
CHEMBL:CHEMBL379975 ? unclear Mechanistic
HESPERADIN inhibits Mechanistic 19.0 nM (Kd)
PHENFORMIN ? unclear Mechanistic
THYROXINE ? unclear Mechanistic
ACADESINE activates Mechanistic
CHEMOPREVENTIVE AGENT ? unclear Mechanistic
SOTRASTAURIN ? unclear Mechanistic 630.96 nM (Ki)
NVP-TAE684 ? unclear Mechanistic
METFORMIN HYDROCHLORIDE activates Mechanistic
SUNITINIB inhibits Mechanistic 52.0 nM (Kd)
ALVOCIDIB inhibits Mechanistic 6600.0 nM (Kd)
STAUROSPORINE inhibits Mechanistic 9.0 nM (Kd)
VANDETANIB inhibits Mechanistic 10000.0 nM (Kd)
AST-487 inhibits Mechanistic 1400.0 nM (Kd)
RAF-265 inhibits Mechanistic 4500.0 nM (Kd)
MIDOSTAURIN inhibits Mechanistic 180.0 nM (Kd)
SU-014813 inhibits Mechanistic 100.0 nM (Kd)

Showing top 40 of 202 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
NERELIMOMAB inhibits Mechanistic
CROMOLYN SODIUM ? unclear Mechanistic
PLACULUMAB inhibits Mechanistic
METHYLENE BLUE ? unclear Mechanistic
ALTEPLASE ? unclear Mechanistic
CARBOPLATIN ? unclear Mechanistic
GENTAMICIN ? unclear Mechanistic
GOLIMUMAB inhibits Mechanistic
BUPIVACAINE ? unclear Mechanistic
PENTOXIFYLLINE ? unclear Mechanistic 85000.0 nM (IC50)
BENZO[E]PYRENE ? unclear Mechanistic
THALIDOMIDE ? unclear Mechanistic
PYRAZINAMIDE ? unclear Mechanistic
GLIMEPIRIDE ? unclear Mechanistic
OMEPRAZOLE ? unclear Mechanistic
LENERCEPT inhibits Mechanistic
ADALIMUMAB inhibits Mechanistic
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic
REMTOLUMAB ? unclear Mechanistic
MIDOSTAURIN ? unclear Mechanistic
LENABASUM ? unclear Mechanistic
MAGNESIUM SULFATE ANHYDROUS ? unclear Mechanistic
PICIBANIL ? unclear Mechanistic
FLUOCINOLONE ACETONIDE ? unclear Mechanistic
MILTEFOSINE ? unclear Mechanistic
HOMIDIUM BROMIDE ? unclear Mechanistic
OZORALIZUMAB inhibits Mechanistic
PEGSUNERCEPT inhibits Mechanistic
CERTOLIZUMAB PEGOL inhibits Mechanistic
THERAPEUTIC HORMONE ? unclear Mechanistic
NAFAMOSTAT ? unclear Mechanistic
FOLIC ACID ? unclear Mechanistic
ABBV-257 ? unclear Mechanistic
RISPERIDONE ? unclear Mechanistic
COVA322 ? unclear Mechanistic
HYDROXYCHLOROQUINE ? unclear Mechanistic
CERTOLIZUMAB ? unclear Mechanistic
AN0128 ? unclear Mechanistic
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic
SORAFENIB ? unclear Mechanistic

Showing top 40 of 277 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT00001721 Phase: N/A Started: 1998-09-13

Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder (autosomal recessive) caused by an abnormality in the production of cholesterol. The disorder can occur in both a "mild" or "severe" form. SLOS is associated with multiple birth defects and mental retardation. Some of the birth defects include;...

NCT00001456 Phase: N/A Started: 1995-11-06

Hermansky-Pudlak Syndrome (HPS) is an inherited disease which results in decreased pigmentation (oculocutaneous albinism), bleeding problems due to a platelet abnormality (platelet storage pool defect), and storage of an abnormal fat-protein compound (lysosomal accumulation of ceroid lipofuscin). T...

NCT00084305 Phase: N/A Started: 2004-06-09

The etiology of pulmonary fibrosis is unknown. Analyses of blood, genomic DNA, and specimens procured by bronchoscopy, lung biopsy, lung transplantation, clinically-indicated extra-pulmonary biopsies, or post-mortem examination from individuals with this disorder may contribute to our understanding ...

NCT00046202 Phase: N/A Started: 2002-10-09

This study will investigate the cause and medical problems associated with a group of genetic disorders known as inborn errors of cholesterol synthesis, in which the body does not produce cholesterol. People with this disorder may have birth defects and learning and behavioral problems. People with...

NCT07649031 Phase: N/A Started: 2026-06-23

This study being done to learn more about the use of medical Magnetic Resonance Imaging (mMRI) and dedicated dental MRI (ddMRI) as a non-invasive diagnosing tool when evaluating potential oral cancerous and precancerous lesions in Fanconi Anemia patients.

NCT02912559 Phase: PHASE3 Started: 2017-10-16

This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). Drugs used in combination chemotherapy, such...

NCT03805919 Phase: N/A Started: 2019-03-27

Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at highe...

NCT07636928 Phase: PHASE1 Started: 2026-06-04

The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.

NCT00078078 Phase: N/A Started: 2004-06-07

Methylmalonic acidemia (MMA), one of the most common inborn errors of organic acid metabolism, is heterogeneous in etiology and clinical manifestations. Affected patients with cblA, cblB and mut classes of MMA are medically fragile and can suffer from complications such as metabolic stroke or infarc...

NCT07571915 Phase: NA Started: 2026-06-01

The primary outcome of interest is change in PCOS health-related quality of life, while the secondary outcome of interest is change in adiposity, cardiometabolic, and inflammation biomarkers.

NCT05632601 Phase: NA Started: 2023-04-25

The full HER CROWN will be a prospective cohort study to propose a novel, women-specific cardiovascular risk score/ algorithm in the prediction of hard cardiovascular outcomes (myocardial infarction, unstable angina, coronary revascularization, stroke, total and cardiovascular mortality). This futur...

NCT04414046 Phase: PHASE2 Started: 2020-07-22

This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition. This study will use stem cells obtained via peripheral blood or bone marrow fr...

NCT06807463 Phase: PHASE2 Started: 2025-03-31

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further...

NCT01143454 Phase: N/A Started: 2010-07-21

Background: \- Researchers are interested in studying individuals who have known or suspected metabolic, inflammatory or genetic diseases that may put them at a high risk for heart diseases or diseases of their blood vessels. Depending on the condition being studied, both affected and nonaffected i...

NCT03655223 Phase: N/A Started: 2018-10-15

Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program....


Agents Found By Disease-Level Search

Searched directly from “Metabolic Syndrome” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.